Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odanacatib in postmenopausal osteoporosis previously treated with alendronate
NCT00885170Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2009
- Primary completion
- Sep 2011
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of odanacatib in postmenopausal osteoporosis, sponsored by Merck & Co.. Started Apr 2009; status: completed.
02
Drugs
odanacatib
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00885170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00885170.